SavedAdd your journal

Journals / Journal of Urological Surgery / 2021 / Cilt: 8 - Sayı: 2

Endoscopic Treatment of Vesicoureteral Reflux: Changing Trends Over the Years

Taner CEYLAN
Burak ÇITAMAK
Ali Cansu BOZACI
Mesut ALTAN
Kamranbay GASİMOV
Tarık ASİ
Hasan Serkan DOĞAN
Serdar TEKGÜL
Pages
123–129
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Statistical analyzes were performed by SPSS 20.0 programme.Results: Overall patient-based and renal unit-based success rates of ESI were 75.6% and 78.2%, respectively.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To investigate factors affecting the success rate of endoscopic subureteral injection (ESI) in patients with vesicoureteral reflux (VUR) andto evaluate the changes in years.Materials and Methods: A total of 439 patients with primary VUR who underwent ESI were included.
📊
Key Findings & Data:Statistical analyzes were performed by SPSS 20.0 programme.Results: Overall patient-based and renal unit-based success rates of ESI were 75.6% and 78.2%, respectively.
💡
Conclusion & Impact:It is performed also in high-grade patients withacceptable success rates which tended to increase over the years
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objective: To investigate factors affecting the success rate of endoscopic subureteral injection (ESI) in patients with vesicoureteral reflux (VUR) andto evaluate the changes in years.Materials and Methods: A total of 439 patients with primary VUR who underwent ESI were included. We used dextranomer hyaluronic acid copolymer (Dx-HA) as bulking agent. Statistical analyzes were performed by SPSS 20.0 programme.Results: Overall patient-based and renal unit-based success rates of ESI were 75.6% and 78.2%, respectively. Operational age of 82 months andlower grades of VUR were found to be the factors increasing success rate (p=0.023, p=0.005). Success rates were as 83.6%, 77.9% and 64.5% forgrades of reflux 1-2, 3 and 4-5, respectively (p=0.002). When patients were seperated into four equal chronological groups, we observed that theratio of patients who had previous failed ESI, high-grade reflux and renal scarring and volume of injected material has increased over the years.Conclusion: ESI has higher success rates in older children and lower grades (grades 1-3) of VUR. It is performed also in high-grade patients withacceptable success rates which tended to increase over the years

🔖

Cite This Article

CEYLAN, T., ÇITAMAK, B., BOZACI, A. C., ALTAN, M., GASİMOV, K., ASİ, T., DOĞAN, H. S., TEKGÜL, S. (2021). Endoscopic Treatment of Vesicoureteral Reflux: Changing Trends Over the Years. Journal of Urological Surgery, Cilt: 8 - Sayı: 2, 123–129. https://ajindex.com/articles/347529

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. Lebowitz RL. The detection and characterization of vesicoureteral reflux in the child. J Urol 1992;148:1640-1642
  2. Peters CA, Skoog SJ, Arant BS Jr, Copp HL, Elder JS, Hudson RG, Khoury AE, Lorenzo AJ, Pohl HG, Shapiro E, Snodgrass WT, Diaz M. Summary of the AUA Guideline on Management of Primary Vesicoureteral Reflux in Children. J Urol 2010;184:1134-1144
  3. Routh JC, Inman BA, Reinberg Y. Dextranomer/hyaluronic acid for pediatric vesicoureteral reflux: systematic review. Pediatrics 2010;125:1010-1019
  4. Kirsch AJ, Arlen AM, Lackgren G. Current trends in dextranomer hyaluronic acid copolymer (Deflux) injection technique for endoscopic treatment of vesicoureteral reflux. Urology 2014;84:462-468
  5. Elder JS, Diaz M, Caldamone AA, Cendron M, Greenfield S, Hurwitz R, Kirsch A, Koyle MA, Pope J, Shapiro E. Endoscopic therapy for vesicoureteral reflux: a meta-analysis. I. Reflux resolution and urinary tract infection. J Urol 2006;175:716-722
  6. Routh JC, Reinberg Y. Predicting success in the endoscopic management of pediatric vesicoureteral reflux. Urology 2010;76:195-198
  7. Capozza N, Lais A, Matarazzo E, Nappo S, Patricolo M, Caione P. Influence of voiding dysfunction on the outcome of endoscopic treatment for vesicoureteral reflux. J Urol 2002;168:1695-1698
  8. Lavelle MT, Conlin MJ, Skoog SJ. Subureteral injection of Deflux for correction of reflux: analysis of factors predicting success. Urology 2005;65:564-567
  9. Dogan HS, Altan M, Citamak B, Bozaci AC, Koni A, Tekgul S. Factors affecting the success of endoscopic treatment of vesicoureteral reflux and comparison of two dextranomer based bulking agents: does bulking substance matter? J Pediatr Urol 2015;11:90
  10. Mattoo TK, Chesney RW, Greenfield SP, Hoberman A, Keren R, Mathews R, Gravens-Mueller L, Ivanova A, Carpenter MA, Moxey-Mims M, Majd M, Ziessman HA; RIVUR Trial Investigators. Renal Scarring in the Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) Trial. Clin J Am Soc Nephrol 2016;11:54-61
  11. Guerra LA, Khanna P, Levasseur M, Pike JG, Leonard MP. Endoscopic treatment of vesicoureteric reflux with Deflux: a Canadian experience. Can Urol Assoc J 2007;1:41-45
  12. Dave S, Bägli DJ. A review of the effect of injected dextranomer/hyaluronic Acid copolymer volume on reflux correction following endoscopic injection. Adv Urol 2008;2008:579370
  13. Sorensen MD, Koyle MA, Cowan CA, Zamilpa I, Shnorhavorian M, Lendvay TS. Injection volumes of dextranomer/hyaluronic acid a